Hrt Financial LP Lineage Cell Therapeutics, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.91 - $1.35 $32,689 - $48,496	35,923 New	35,923 $39,000
Q2 2023 Aug 11, 2023	BUY	$1.26 - $1.53 $624,012 - $757,729	495,248 Added 198.59%	744,628 $1.05 Million
Q1 2023 May 12, 2023	BUY	$1.2 - $1.53 $275,005 - $350,631	229,171 Added 1134.0%	249,380 $374,000
Q4 2022 Feb 10, 2023	BUY	$1.02 - $1.5 $20,613 - $30,313	20,209 New	20,209 $23,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $163,439 - $334,983	-135,074 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $248,536 - $361,998	135,074 New	135,074 $330,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $627,169 - $867,054	-289,018 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $511,561 - $895,955	289,018 New	289,018 $679,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.